|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.38 | 89.41 | 104.18 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
161.70
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | UnAudited | Net Sales | 525.07 | 494.48 | 426.70 | 507.54 | Total Expenditure | 497.08 | 467.41 | 401.49 | 484.74 | PBIDT (Excl OI) | 27.99 | 27.07 | 25.21 | 22.80 | Other Income | 1.30 | 2.39 | 2.20 | 6.89 | Operating Profit | 29.30 | 29.45 | 27.41 | 29.69 | Interest | 14.47 | 14.88 | 12.89 | 9.52 | Exceptional Items | 0 | 0 | 0 | 0 | PBDT | 14.83 | 14.57 | 14.52 | 20.17 | Depreciation | 13.30 | 13.20 | 12.94 | 12.59 | Profit Before Tax | 1.53 | 1.37 | 1.58 | 7.58 | Tax | 1.35 | 1.08 | 1.24 | 6.46 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 0.18 | 0.29 | 0.34 | 1.12 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 0.18 | 0.29 | 0.34 | 1.12 | Equity Capital | 80.00 | 80.00 | 80.00 | 80.00 | Face Value (IN RS) | 10 | 10 | 10 | 10 | Reserves | 379.74 | 382.8 | 382.5 | 382.15 | Calculated EPS | 0.02 | 0.04 | 0.04 | 0.14 | Calculated EPS (Annualised) | 0.09 | 0.14 | 0.17 | 0.56 | No of Public Share Holdings | 2,067,969.00 | 2,067,969.00 | 2,067,969.00 | 2,067,969.00 | % of Public Share Holdings | 25.85 | 25.85 | 25.85 | 25.85 | | | | | | PBIDTM% (Excl OI) | 5.33 | 5.47 | 5.91 | 4.49 | PBIDTM% | 5.58 | 5.96 | 6.42 | 5.85 | PBDTM% | 2.82 | 2.95 | 3.40 | 3.97 | PBTM% | 0.29 | 0.28 | 0.37 | 1.49 | PATM% | 0.03 | 0.06 | 0.08 | 0.22 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|